PD-L1 on tumor cells, thereby driving tumor adaptive immune resistance. Our ?ndings thus indicate that the blockade of the PD-1/PD-L1 pathway prevents the adaptive immune resistance induced by Folfox in colorectal cancers. Results Folfox combined with anti-PD-1 therapy induces complete colorectal tumor cure, 2/17/2016 · Two patients who developed adaptive resistance to anti-PD-1 treatment also show a similar TIM-3 upregulation in blocking antibody-bound T cells at treatment failure.
Oncogenic driver mutations in several tumor types promote constitutive PD-L1 expression, a crucial ligand in PD-1-mediated tumor immune escape. Our studies in melanoma suggest a different mechanism–one of “ adaptive immune resistance ” in which PD-L1 expression is primarily driven by cytokine induction and is independent of BRAF mutational …
Ghiringhelli & Lionel Apetoh (2018) PD-1/ PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic chemotherapy in colorectal cancer , OncoImmunology, 7:6, e1433981, DOI: 10.1080 …
2/9/2017 · PD-L1 expression can be constitutive or induced in many tumors to evade immune attack. Since PD-L1 expression can be induced by IFN?, which is expressed during an active anti-tumor immune response, it has been referred to as a mechanism of adaptive immune resistance .
These findings demonstrate that PD-L1 expression indicates an adaptive immune resistance mechanism adopted by tumor cells in the aversion of immunogenic destruction by CD8 + TILs. Both higher expression of PD-L1 and infiltration of CD8 + TILs were correlated with superior prognosis (p = 0.044 for PD-L1 p = 0.002 for CD8). Moreover, Cox multivariate regression.
Programmed cell death-ligand 1 (PD-L1) expressed on tumors is thought to inhibit tumor-infiltrating lymphocytes (TILs) through programmed cell death 1 (PD1), enabling adaptive immune resistance. This study investigates the role of PD-L1 in …
